Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Former Aventis Exec Hofstaetter Finds A New Home At Wyeth

This article was originally published in The Pink Sheet Daily

Executive Summary

Thomas Hofstaetter is responsible for business and corporate development as a senior VP, reporting to Wyeth CEO Robert Essner and Pharmaceuticals President Bernard Poussot.

You may also be interested in...



Sanofi-Aventis Business Development Head Hofstaetter To Resign

Thomas Hofstaetter was to be one of 10 former Aventis employees to join the merged board's management committee. Sanofi-Aventis says it will still meet its Jan. 1 deadline for having a new operational structure in place.

Sanofi-Aventis Picks Two To Head U.S.: Rothwell, Soriot On Management Committee

Sanofi's Tim Rothwell will continue to serve as U.S. CEO, while Aventis' Soriot will head U.S. commercial operations. French market regulator extends closing date of merger to July 30, citing extra time needed for FTC review.

Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues

“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel